Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Myelodysplastic Syndromes 3Primary Myelofibrosis 2Myeloproliferative Disorders 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2Thrombocytosis 1Rhabdomyosarcoma 1Recurrence 1Polycythemia 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hepatoblastoma 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1Brain Stem Neoplasms 1Astrocytoma 1

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × GRN163L peptide × Clear all
NCT01242930 2016-05-12

Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma

Geron Corporation

Phase 2 Completed
13 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡